Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion

Hall, Leangelo N.; Frizzera, Luma Paiva; Coelho, Laura Fernandes; Carricondo, Pedro Carlos; Oyamada, Maria Kiyoko; Pimentel, Sérgio Luís Gianotti; Abalem, Maria Fernanda

doi:10.1186/s40942-019-0183-x

Cited by 6 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study by Leangelo Hall et al, 12 the baseline BCVA was Log MAR 1.3 and CMT as 858 ± 311 microns comparable to the findings in ischaemic CRVO in our study.…”

Section: Discussionsupporting

confidence: 91%

A study on the effect of Anti- VEGF on retinal venous occlusive disease with macular edema in a tertiary health care centre of southern Assam

Das,

Thakur,

Das

et al. 2023

IJCEO

View full text Add to dashboard Cite

Macular oedema is considered to be the primary reason for significant visual loss and impaired visual recovery in patients with retinal venous occlusion and rise in VEGF is strongly implicated in macular edema and as such there is a good rationale in treating these conditions with intravitreal anti-vascular endothelial growth factors. Aim of this study was to assess the effect of anti-VEGF (Bevacizumab) on retinal venous occlusive disease with macular edema.This was prospective open label hospital based interventional study done from June 2021 to May 2022 in fifty eyes of fifty patients diagnosed with macular edema secondary to retinal venous occlusion and Snellen’s visual acuity at presentation of less than 6/12 were included in accordance with the inclusion and exclusion criteria.The results shows statistically significant improvement in mean central macular thickness and mean Snellen’s visual acuity at the end of 12 months and factors like Hypertension, Diabetes mellitus, Dyslipidemia and smoking are found to be highly associated with retinal venous occlusive diseases. The intravitreal anti-VEGF (Bevacizumab) has been found to be effective in improving the macular edema and visual acuity in the study population with retinal venous occlusive diseases to a statistically significant level and that it was more pronounced in cases of BRVO, at the completion of the study period.

show abstract

“…In another study by Leangelo Hall et al, 12 the baseline BCVA was Log MAR 1.3 and CMT as 858 ± 311 microns comparable to the findings in ischaemic CRVO in our study.…”

Section: Discussionsupporting

confidence: 91%

A study on the effect of Anti- VEGF on retinal venous occlusive disease with macular edema in a tertiary health care centre of southern Assam

Das,

Thakur,

Das

et al. 2023

IJCEO

View full text Add to dashboard Cite

show abstract

“…06, Jun 2022 303 edema. 15,16 There was a significant level of (P < 0.01) correlation between the mean change in CMT of all study stages and the mean change in BCVA. One month after each injection, BCVA improved significantly, as a result of reduced macular edema and vascular leakage.…”

Section: Discussionmentioning

confidence: 80%

Comparison of Suprachoroidal Triamcinolone Injection with Intravitreal Bevacizumab Vs Intravitreal Bevacizumab only in Treatment of Refractory Diabetic Macular Edema

Shahid¹,

Rashid²,

Tauqeer³

et al. 2022

PJMHS

View full text Add to dashboard Cite

Background: Macular edema due to diabetic retinopathy is among the most common causes of blindness in diabetics from working age group around the world . Diabetic macular edema which involves the center of the macula is among the major cause of visual decline in patients with diabetes mellitus. Intra-Vitreal Triamcinolone Acetonide with intravitreal Bevacizumab and intravitreal Bevacizumab only have been in practice as treatment options for cases not responsive to anti-vascular endothelial growth factor agents. Objective: To compare safety and efficacy profile of suprachoroidal injection of triamcinolone acetonide with intravitreal Bevacizumav Vs intravitreal injection of Bevacizumab alone in management of resistant diabetic macular edema. Patients & Methods: In this study, Fourty eyes of fourty patients who had resistant diabetic macular edema were randomly divided into two groups of 20 patients each (n=20) , our group A was injected with suprachoroidal triamcinolone acetonide 2 mg along with intravitreal Bevacizumab 1.25mg and the group B wasinjected with intravitreal Bevacizumab 1.25 mg only. Change in central macular thickness was observed after one month on Optical coherence tomography. Data was collected and analyzed by using SPSS software. Results: The mean age of subjects in this study was 58.46±3.62 years ( 30-65 years) . Out of 40 patients 26 were male patients and 14 were female .The mean decline (change) in central macular thickness in comparison to baseline thickness on OCT in group A was 113±10microns and mean change in the central thickness of macula on OCT in group B was 83+-10 microns with a p value of 0.01. Conclusion: Suprachoroidal triamcinolone acetonide with intravitreal bevacizumab is superior to intravitreal Bevacizumab alone in reducing central macular thickness among patients with resistant diabetic macular edema. Keywords: Macular edema, Suprachoroidal triamcinolone , intravitreal Bevacizumab, Optical coherence tomography

show abstract

“…Hall et al . [ 22 ] found no visual gains in ischemic CRVO despite giving anti-VEGF for six months. In RAVE, 50% of patients developed neovascular complications, despite intensive anti-VEGF therapy.…”

Section: Discussionmentioning

confidence: 99%

“…These studies concluded that anti-VEGF in ischemic CRVO can decrease macular edema but cannot prevent neovascular complications. [ 21 22 ]…”

Section: Discussionmentioning

confidence: 99%

Long-term real-world outcomes in retinal vein occlusions: How close are we to the trials?

Shah

Shanmugam

Vora

et al. 2022

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To assess and analyze the visual outcomes of patients with retinal vein occlusions in a real-world setting with a long-term follow-up of more than 5 years. Methods: Retrospective analysis of 56 patients having retinal vein occlusions from a tertiary eye center, with a mean follow-up of 7 years was performed. Primary outcome measures were mean change in best-corrected visual acuity (BCVA) from baseline at 6 months, 1 year, 2 years, 3 years, and final visit (≥5 years), proportion of patients having BCVA better than 20/40 and worse than 20/200, and mean number of injections. Secondary outcome measures were change in central macular thickness (CMT), development of subsequent retinal vein occlusion (RVO) in same eye or the other eye, and development of neovascular complications. Results: The mean change in letter score was + 11.84 in branch RVO (BRVO), +7.14 in non-ischemic central RVO (CRVO), and −9.5 in ischemic CRVO at 1 year, which changed to + 8.57, −5 and − 24, respectively, at the end of follow-up. CMT had improved from 506 ± 98.8 µm, 576.44 ± 149 µm, and 618 ± 178.27 µm, respectively, at baseline to 267 ± 94 µm, 345.20 ± 122.61 µm, and 265.50 ± 107.75 µm, respectively, in BRVO, non-ischemic, and ischemic hemi RVO (HRVO)/CRVO groups. The total mean number of injections given in BRVO, non-ischemic CRVO, and ischemic CRVO groups were 4.6, 6.6, and 4.1, respectively. None of the patients with BRVO developed neovascular glaucoma (NVG). Non-ischemic to ischemic HRVO/CRVO conversion was noted in 4/11 eyes at a mean duration of 12.6 months. NVG was noted in 7/9 eyes (77.8%) in initial ischemic CRVO/HRVO group and 3/4 (75%) converted eyes. Conclusion: Patients with BRVO have good visual outcomes with anti-VEGF, while in CRVO results may vary considerably owing to patient compliance and treatment burden on long-term follow-up in a real-world setting.

show abstract

Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion

Cited by 6 publications

References 24 publications

A study on the effect of Anti- VEGF on retinal venous occlusive disease with macular edema in a tertiary health care centre of southern Assam

A study on the effect of Anti- VEGF on retinal venous occlusive disease with macular edema in a tertiary health care centre of southern Assam

Comparison of Suprachoroidal Triamcinolone Injection with Intravitreal Bevacizumab Vs Intravitreal Bevacizumab only in Treatment of Refractory Diabetic Macular Edema

Long-term real-world outcomes in retinal vein occlusions: How close are we to the trials?

Contact Info

Product

Resources

About